MX2011012576A - Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo. - Google Patents

Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.

Info

Publication number
MX2011012576A
MX2011012576A MX2011012576A MX2011012576A MX2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A
Authority
MX
Mexico
Prior art keywords
highly concentrated
produce
immunoglobulin preparation
subcutaneous use
concentrated immunoglobulin
Prior art date
Application number
MX2011012576A
Other languages
English (en)
Inventor
Wolfgang Teschner
Hans-Peter Schwarz
Harald Arno Butterweck
Azra Pljevljakovic
Theresa Friederike Bauer
Bernhard Koelbl
Nebojsa Nikolic
Gerhard Poelsler
Johanna Kindermann
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2011012576A publication Critical patent/MX2011012576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método novedoso y mejorado para preparar una composición altamente concentrada de inmunoglobulina a partir de plasma combinado para una inyección subcutánea. Composición de uso subcutáneo que comprende 20% o más de inmunoglobulina.
MX2011012576A 2009-05-27 2010-05-27 Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo. MX2011012576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18160609P 2009-05-27 2009-05-27
PCT/US2010/036430 WO2010138736A2 (en) 2009-05-27 2010-05-27 A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Publications (1)

Publication Number Publication Date
MX2011012576A true MX2011012576A (es) 2012-05-08

Family

ID=42335649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012576A MX2011012576A (es) 2009-05-27 2010-05-27 Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.

Country Status (18)

Country Link
US (5) US8546548B2 (es)
EP (3) EP2762492A3 (es)
JP (1) JP5341252B2 (es)
KR (1) KR101464032B1 (es)
CN (1) CN102459331B (es)
AR (1) AR076607A1 (es)
AU (6) AU2010253830B2 (es)
BR (1) BRPI1012082B1 (es)
CA (1) CA2763138A1 (es)
CL (2) CL2011002996A1 (es)
CO (1) CO6480954A2 (es)
EA (1) EA023382B1 (es)
HK (1) HK1200843A1 (es)
MX (1) MX2011012576A (es)
MY (1) MY157239A (es)
SG (1) SG176256A1 (es)
TW (1) TWI445714B (es)
WO (1) WO2010138736A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
BR112012002574A2 (pt) 2009-08-06 2020-11-03 Genentech, Inc. método para aprimorar a remoção de vírus na purificação de proteínas
MX2012003282A (es) * 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
FR2962650B1 (fr) * 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
JP6055412B2 (ja) 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
AR087953A1 (es) 2011-08-26 2014-04-30 Baxter Int Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma
EP2758076B1 (en) 2011-09-24 2018-12-12 CSL Behring GmbH Combination therapy using immunoglobulin and c1-inhibitor
DK2791675T3 (da) 2011-12-13 2018-07-30 Baxalta GmbH Måling af autoantistoffer under lav ledeevne-betingelser
CN102532307B (zh) * 2012-02-22 2013-06-12 成都蓉生药业有限责任公司 一种制备人免疫球蛋白的方法
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
JP6224586B2 (ja) * 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR102238133B1 (ko) * 2013-11-15 2021-04-09 제넨테크, 인크. 환경-친화적 세제를 사용한 바이러스 불활성화 방법
WO2016161418A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang A method of manufacturing an afod intra venous injection from fraction iv
EP3302529A4 (en) 2015-06-03 2019-02-06 The Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING GALLENA GANGATRESIA IN NEWBORNS
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
FR3081328B1 (fr) * 2018-05-24 2021-01-01 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN113795275A (zh) * 2019-04-18 2021-12-14 詹森生物科技公司 唾液酸化糖蛋白
AU2023230335A1 (en) 2022-03-07 2024-08-29 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
CN117069836B (zh) * 2023-09-22 2024-08-27 武汉中生毓晋生物医药有限责任公司 一种抗人t细胞兔免疫球蛋白的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3929411A1 (de) 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
US4892826A (en) 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AT405739B (de) 1997-09-19 1999-11-25 Immuno Ag Verfahren zur reinigung von antithrombin iii
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AU753468B2 (en) * 1998-06-09 2002-10-17 Csl Behring Ag Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
WO2005023867A1 (en) 2003-09-08 2005-03-17 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
KR20070009995A (ko) * 2004-01-30 2007-01-19 수오멘 푸나이넨 리스티 베리팔베루 바이러스 안전성 면역글로불린을 제조하는 방법
DK1718675T3 (da) 2004-02-27 2013-07-15 Octapharma Ag Fremgangsmåde til at tilvejebringe en oprenset virussikker antistoftilberedning
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP5555626B2 (ja) 2007-08-13 2014-07-23 バクスター・インターナショナル・インコーポレイテッド 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節
CN101279246B (zh) * 2007-12-28 2011-07-27 华侨大学 一种嗜硫性磁性复合微球的制备方法和用此复合微球分离免疫球蛋白g的方法
EP2271382B1 (en) 2008-04-15 2013-03-13 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法

Also Published As

Publication number Publication date
EP3708581A3 (en) 2021-10-20
MY157239A (en) 2016-05-13
AU2010253830A1 (en) 2011-12-15
CO6480954A2 (es) 2012-07-16
CA2763138A1 (en) 2010-12-02
BRPI1012082A2 (pt) 2019-04-02
SG176256A1 (en) 2012-01-30
EP2762492A3 (en) 2015-03-18
US10125189B2 (en) 2018-11-13
US11242380B2 (en) 2022-02-08
EP3708581A1 (en) 2020-09-16
AU2024203600A1 (en) 2024-06-20
EP2435474A2 (en) 2012-04-04
EA201171481A1 (ru) 2012-07-30
US20190085064A1 (en) 2019-03-21
US20220153823A1 (en) 2022-05-19
AU2022228125A1 (en) 2022-09-29
WO2010138736A2 (en) 2010-12-02
AU2010253830B2 (en) 2016-03-03
JP2012528190A (ja) 2012-11-12
US9175068B2 (en) 2015-11-03
US20160244512A1 (en) 2016-08-25
KR20140014403A (ko) 2014-02-06
US20100330071A1 (en) 2010-12-30
AU2020204244B2 (en) 2022-08-18
AU2022228125B2 (en) 2024-02-29
US8546548B2 (en) 2013-10-01
AU2016203542B2 (en) 2018-02-15
US20140030252A1 (en) 2014-01-30
AU2020204244A1 (en) 2020-07-16
EP2762492A2 (en) 2014-08-06
AU2016203542A1 (en) 2016-06-16
TWI445714B (zh) 2014-07-21
BRPI1012082B1 (pt) 2022-08-16
AR076607A1 (es) 2011-06-22
HK1200843A1 (en) 2015-08-14
JP5341252B2 (ja) 2013-11-13
CN102459331A (zh) 2012-05-16
CN102459331B (zh) 2015-01-28
CL2013001673A1 (es) 2013-12-06
EA023382B1 (ru) 2016-05-31
WO2010138736A3 (en) 2011-03-17
KR101464032B1 (ko) 2014-11-27
CL2011002996A1 (es) 2012-10-19
AU2018200548B2 (en) 2020-04-02
TW201107344A (en) 2011-03-01
AU2018200548A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
MY157239A (en) A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX343756B (es) Microorganismo que produce o-fosfoserina y metodo para producir l-cisteina o derivados de la misma a partir de o-fosfoserina usando los mismos.
IN2012DN03883A (es)
MX2018008597A (es) Composiciones inyectables de melfalan que comprenden un derivado de ciclodextrina y metodos de fabricacion y uso de las mismas.
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2012004780A (es) Inhibidores de akt.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MY156769A (en) Heat-aging-resistant polyamides
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
IN2012DN03379A (es)
MX339361B (es) Derivados de alternano.
MX2010009931A (es) Proceso para la preparacion de 2-amino-2-[2-(4-c3-c21-alquil-fenil )-etil]-propano-1,3-dioles.
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
EA201270390A1 (ru) 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
IN2014DN03245A (es)
WO2010059916A3 (en) Preparation of docetaxel
NZ600978A (en) Vaccine compositions
IN2012DN00346A (es)

Legal Events

Date Code Title Description
FG Grant or registration